{
  "docId": "019de075-5029-738c-8512-9456f77efe7c",
  "docSlug": "25c628cfc0779f52594519f9e322dc70",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 38,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide uses a document-style container for patient background and icon-based lists for clinical outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5029-738c-8512-9456f77efe7c/11",
  "deckHref": "/decks/019de075-5029-738c-8512-9456f77efe7c",
  "deckJsonHref": "/decks/019de075-5029-738c-8512-9456f77efe7c.json",
  "deckAnchorHref": "/decks/019de075-5029-738c-8512-9456f77efe7c#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.51,
        "y": 0.66
      },
      "kind": "list",
      "text": "Translational Evidence: Activation of tumor-specific T cell response detected in blood, Documented immune activation in tumor microenvironment with significant influx of TILs, Favorable immune-related genetic signatures",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d8e32d9-25e8-4b8a-9897-ef5247c5c657",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.51,
        "y": 0.44
      },
      "kind": "list",
      "text": "Antitumor activity: Clinical Benefit Rate: 73% (8/11), 4/11 patients had >2x PFS relative to immediate prior chemotherapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8710d9a-f790-4412-8b5c-217def62e2de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.51,
        "y": 0.22
      },
      "kind": "list",
      "text": "Tolerability: No Dose Limiting Toxicity (DLT), No Maximum Tolerated Dose (MTD), No Grade 4 Adverse Events (AE)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d89d5fcc-41b6-4f9d-9390-e1d25cd40de7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.04,
        "y": 0.185
      },
      "kind": "paragraph",
      "text": "Patient Background & Study Treatment\n\nPlatinum-resistant / refractory ovarian cancer\n\nHeavily pre-treated patients with documented progressive disease at baseline\n\nSingle cycle of high & condensed bolus infusions (intraperitoneal delivery) on 2 consecutive days; total dose: 6x10^9 pfu",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "246eb8f4-ab88-44d1-9876-ccc4080dca55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.65,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Manyam et al., Gynecologic Oncology 163 (2021) 481 - 489",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eae5f233-06d6-46d5-af15-a320eac82e70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Phase 1b: Anti-tumor Activity as Monotherapy Leading into Combination",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee01335c-81fc-4e22-b2e7-6625eab1a460",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}